In this section
The Network aims to promote multi-disciplinary approaches to address challenging vaccine-related questions. This page contains a curated list of publications that highlight high-impact and collaborative approaches.
@article{Habibi:2016:10.1016/j.vaccine.2016.08.086,
author = {Habibi, MS and Chiu, C},
doi = {10.1016/j.vaccine.2016.08.086},
journal = {Vaccine},
pages = {489--495},
title = {Controlled human infection with RSV: the opportunities of experimental challenge},
url = {http://dx.doi.org/10.1016/j.vaccine.2016.08.086},
volume = {35},
year = {2016}
}
TY - JOUR
AB - Despite the recent explosion in RSV vaccine development, there remain substantial hurdles to overcome before licensing of effective vaccines will allow widespread use, particularly in high-risk populations. Incomplete understanding of mechanisms and correlates of protection against RSV mean that, for the time being, successful RSV vaccines must directly demonstrate efficacy, which necessitates large and costly clinical trials in naturally infected patients. To mitigate the risks inherent in progressing to these late-stage trials, experimental human RSV infection studies have recently been re-established, representing the interface between pre-clinical models and observational studies of patients. Not only can they be used for early proof-of-concept clinical trials to test vaccine efficacy, but human challenge studies also offer the potential to better understand protective immunity against RSV infection to improve vaccine design and delivery. In the past, controlled human infection studies with RSV have been instrumental in elucidating the influence of factors such as route of infection and type of inoculum on the course of disease. Recently, efficacy trials of novel RSV antiviral drugs have also been successfully undertaken. Now, with advances in technology, detailed investigations of human mucosal immunity in the RSV-infected airway are possible. These have indicated defects in RSV-induced humoral and CD8+ T cell immunity that may contribute to the recurrent symptomatic infection that occurs throughout life and should be circumvented by optimal vaccines. Here, we discuss the insights derived from RSV human challenge models; the major impediments to their more widespread uptake; and their potential benefit in accelerating vaccine development, including future directions to further enhance the relevance of these models to at-risk patient populations.
AU - Habibi,MS
AU - Chiu,C
DO - 10.1016/j.vaccine.2016.08.086
EP - 495
PY - 2016///
SN - 1873-2518
SP - 489
TI - Controlled human infection with RSV: the opportunities of experimental challenge
T2 - Vaccine
UR - http://dx.doi.org/10.1016/j.vaccine.2016.08.086
UR - http://www.ncbi.nlm.nih.gov/pubmed/27889256
UR - http://hdl.handle.net/10044/1/43324
VL - 35
ER -
Clinical Senior Lecturer
Dr Christopher Chiu
vaccine.network@imperial.ac.uk
+44 (0)20 8383 2301
